Pharmacokinetics of monoclonal antibodies implications for their use in cancer therapy

Clinical Immunotherapeutics

Volumn 6, Issue 1, 1996, Pages 54-67

  Pedley, R Barbara ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AMINOPTERIN; ANTIBODY CONJUGATE; IMMUNOTOXIN; MACROGOL; MITOFLAXONE; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ANTIGEN BINDING; CANCER INHIBITION; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TUMOR LOCALIZATION;

EID: 0029785102     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259352     Document Type: Article

References (105)

1. Chester KA, Hawkins RE, Advances in antibody technology tor targeted cancer therapy. Tumour Marker Update 1994; 6: 187-95
2. Mach J-P, Carrel S, Merenda C, et al, In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 1974; 248: 704-6
3. Jain RK, Transport of molecules in the tumour interstitium: a review. Cancer Res 1987; 47: 3039-51
4. Yuan F, Baxter LT, Jain RK, Pharmacokinetic analysis of twostep approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991 ; 51: 3119-30
5. Pedley RB, Begent RHJ, Boden JA, et al, Relationship between tumour size and uptake of radiolabelled anti-CEA antibody in a colon tumour xenograft. Eur J Nucl Med 1987; 13: 197-202
6. Sedlacek H-H, Seemann G, Hoffmann D, et al., editors. Antibodies as carriers of cytotoxicity. Basel: Karger, 1992
7. Dillman RO, Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497-515
8. Hale G, Dyer MJS, Clark MR, et al, Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; II: 1394-9
9. Riethmuller G, Schneider-Gadicke E, Schlimok G. et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83
10. Ragnhammar P, Fagerberg J, Frodin J-E. et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 1993; 53: 751-8
11. Begent RHJ, Targeted therapies: cell surface targets. In: Ponder B. Waring MJ, editors. The science of cancer treatment (cancer biology and medicine) vol 2. Dordrecht: Kluwer Academic Publications. 1990: 161-84
12. Herlyn D, Wettendorff M, Schmoll E, et al, Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sei USA 1987: 84: 8055-9
13. Durrant LG, Buckley D, Denton GWL, et al. Enhanced cell mediated tumour killing in patients immunised with human monoclonal anti-idiotype antibody. Cancer Res 1994; 54: 4837-40
14. Mitteiman A, Chen ZY. Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sei USA 1992; 89: 466-70
15. Buchsbaum DJ, Langmuir VK, Wessels BW, Experimental radioimmunotherapy. Med Phys 1993: 20 Pt 2: 551-67
16. Reilly RM, Radioimmunotherapy of malignancies. Clin Pharm 1991; 10: 359-75
17. Sharkey RM, Pykett MJ. Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonie tumour xenograft with labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987; 47: 5672-7
18. Buchegger F, Vacca F, Carrel S, et al. Radioimmunotherapy ol human colon carcinoma by ' ''I labeled monoclonal anti-CEA antibodies in the nude mouse model. Int J Cancer 1988: 41: 127-34
19. Pedley RB, Boden JA, Boden R. et al. Comparative radioimmunotherapy using intact or Flab'b fragments of 'I antiCEA antibody in a colonie xenograft model. Br J Cancer 1993: 68: 69-73
20. Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer. CurrOpin Immunol 1994; 6: 715-21
21. Lane DM, Eagle KF. Begent RHJ, et al. Radioimmunotherapy of metastatic coiorectal tumours with iodine-'-labelled antibody to carcinoembryonic antigen: phase I/I! study with comparative biodistribution of intact and F(ab'): antibodies. Br J Cancer 1994:70:521-5
22. Kaminski MS, Zasadny KR, Francis IR. et al. Radioimmunotherapy of B-cell lymphoma with Mll anti-BI (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65
23. Press OW, Eary IF, Appelbaum FR. et al. Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-22
24. Beaumier PL, Venkatesan P, Vanderheyden J-L, et al. l8fRe radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 1991 ; 51: 676-8 !
25. Gerretsen M, Visser GWM, Walsum M, et al, IS6Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 1993; 53: 3524-9
26. Smith A, Alberto R, Blaeuenstein Pet al. Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res 1993: 53: 5727-33
27. DeNardo GL, DeNardo SJ, Meares CF, et al. Pharinacokinetics of copper-67 conjugated Lym-1. a potent therapeutic radioimmunoconjugate. in mice and in patients with lymphoma. Antibody Immunoconjug Radiopharm 1991: 4: 777-85
28. King DJ, Turner A. Farnsworth APH, et al. Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54: 6176-85
29. Turner A, King DJ, Farnsworth APH, et al. Comparative biodistribution of indium-111-labelled macrocycle chimeric B72.3 antibody in tumour-bearing mice. Br J Cancer 1994; 70:35-41
30. Woo DV, Li D, MattisJA.etal. Selective chromosomal damage and cytotoxicity of '-4-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res 1989; 49: 2952-8
31. Harrison A, Royle L, Efficacy of astatine-211 -labeled monoclonal antibody in treatment of murine T-cell lymphoma. Nail Cancer In.st Monogr 1987; 3: 157-8
32. Zalutsky MR, McLendon RE, Garg PK. et al. Radioimmunotherapy of neoplastic meningitis in rats using an a-particle emitting immunoconjugate. Cancer Res 1994; 54: 4719-25
33. Huneke RB, Pippin CG, Squire RA, et al. Effective rx-particlemediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 5818-20
34. Hartmann F, Horak EM, Garmestani K, et al, Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor a expressing lymphoma utilising the -emitting radionuclideconjugated monoclonal antibody 2i:Bi-anti-Tac. Cancer Res 1994:54:4362-70
35. Zalutsky MR, Antibody-mediated radiotherapy: future prospects. In: Zalutzky MR, editor. Antibodies in radiodiagnostics and therapy. Boca Raton (FL): CRC Press. 1989
36. Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted ther apy of athymic mice bearing GW-39 human colonie cancer micrometastases with '[-labeled monoclonal antibodies. Cancer Res 1992: 52: 6036-44
37. O'Dwyer PJ, Mojzisik CM, Hinkle G. et al. Intraoperative probe-directed radio-immunodetection using a monoclonal antibody. Arch Surg 1986; 121: 1391-4
38. Theodorou NA, Radioimmunoguided surgery for colorectal cancer. Proceedings of the Tufton Trust Conference on New Antibody Technology and the Emergence of Useful Cancer Therapy; 1994 Oct 10-11 : London. London: Royal Society of Medicine, 1995:51-2
39. Paganelli G, Stella M, De Nardi P, et al, A new method for faster blood clearance in radioimmuno-guided surgery. J Nucl Med Allied Sei 1990; 35: 88-9
40. Paganelli G, Belloni C, Magnani P, et al, Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992; 19: 322-9
41. Bamias A, Bowles MJ, Krausz T, el al, Intravesical administration of indium'-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 1993; 54: 899-903
42. Roeske JC, Chen TY, Brill AB, Dosimetry of intraperitoneally administered radiolabelled antibodies. Med Phys 1993; 20 Pt 2:593-600
43. Britton KE, Overview of radioimmunotherapy: a European perspective. Antibody Immunoconjug Radiopharm 1991 ; 4 Pt 2: 133-50
44. Hird V, Maraveyas A, Snook D, et al, Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403-6
45. Pedley RB, Begent RHJ, Boden JA, et al, The effect of radiosensitizers on radioimmunotherapy, using 'I-labelled antiCEA antibodies in a human colonie xenograft model. Int J Cancer 1991; 47: 597-602
46. Langmuir VK, Mendonca HL, The combined use of ' 3 'I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiât Res 1992; 132: 351-8
47. Ghetie M-A, Vitetta ES, Recent developments in immunotoxin therapy. Curr Opin Immunol 1994; 6: 707-14
48. Amlot PL, Stone MJ, Cunningham D, et al, A phase I study of an anti-CD22 deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-33
49. Vitetta ES, Thorpe PE, Uhr JW, Immunotoxins: magic bullets or misguided missiles. Immunol Today 1993; 14: 252-9
50. Zangemeisterwittke U, Collinson AR, Fisch I, et al, Anti-tumour activity of a blocked ricin immunotoxin with specificity against the cluster-5a antigen associated with human smallcell lung cancer. Int J Cancer 1993; 54: 1028-35
51. Kreitman RJ, Hansen HJ, Jones AL, et al, Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 1993; 53: 819-25
52. Debinski W, Pastan I, Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res 1992; 52: 5379-85
53. Siegall CB, Chace D, Mixan B, et al, In vitro and in vivo characterization of BF96 sFv-PE40. J Immunol 1994; 152: 2377-84
54. Koppel GA, Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconjug Chem 1990; 1: 13-21
55. Hinman LM, Hamann PR, Wallace R, et al, Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumour antibiotics. Cancer Res 1993; 53: 3336-42
56. Shih LB, Xuan H, Sharkey RM, et al, A fluouridine-anti-CEA immunoconjugate is therapeutically effective in a human coIonic cancer xenograft model. Int J Cancer 1990; 46: 1101-6
57. Huennekens FM, Tumour targeting: activation of prodrugs by enzyme monoclonal antibody conjugates. Trends Biotechnol 1994; 12:234-9
58. Begent RHJ, Pedley RB, Monoclonal antibody administration: current clinical pharmacokinetic status and future trends. Clin Pharmacokinet 1992; 23 Pt 2: 85-9
59. Buchegger F, Pelegrin A, Delaloye B, et al, lodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990; 31: 1035-44
60. Schott ME, Frazier KA, Pollock DK, et al, Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumour antibody fragments. Bioconjug Chem 1993; 4: 153-65
61. Pedley RB, Boden JA, Boden R, et al, The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994; 70: 1126-30
62. Kitamura K, Takahashi TK, Yamaguchi T, et al, Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer therapy. Cancer Res 1991 ; 51:4310-5
63. Delgardo C, Pedley RB, Herraez A, et al, Enhanced tumour specificity of an anti-carcinoembryonic antigen Fab' fragment by poly(ethylene glycol) (PEG)-modification. Br J Cancer 1996; 73: 175-82
64. Marshall D, Pedley RB, Boden JA, et al, Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 1996; 73: 565-72
65. McCafferty J, Griffiths J, Winter G, et al, Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-4
66. Chester KA, Begent RHJ, Robson L, et al, Phage libraries for the generation of clinically useful antibodies. Lancet 1994; 343: 455-6
67. Yokata T, Milenik DE, Whitlow M, et al, Rapid tumour penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-8
68. Savage P, So A, Spooner RA, et al, A recombinant single-chain Fv antibody interleukin-2 fusion protein. Br J Cancer 1993; 67:304-10
69. Michael NP, Chester KA, Melton RG, et al, In vitro and in vivo characterisation of a recombinant carboxypeptidase G2-antiCEA scFv fusion protein. Immunotechnology 1996; 2: 47-57
70. Begent RHJ, Bagshawe KD, Green AJ, et al, Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet 1982; II: 739-42
71. Begent RHJ, Bagshawe KD, Pedley RB, et al, Use of second antibody in radioimmunotherapy. Nat! Cancer Inst Monogr 1987:3:59-61
72. Goldenberg DM, Sharkey RM, Ford E, Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J Nucl Med I987;28:1604-10
73. Pedley RB, Dale R, Boden JA, et al, The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonie tumour xenograft model. IntJ Cancer 1989:43:713-18
74. Marshall D, Pedley RB, Boden JA, et al, Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br J Cancer 1994; 69: 502-7
75. Marshall D, Pedley RB, Melton RG, et al, Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an antitumour antibody. Br J Cancer 1995; 71: 18-24
76. Paganelli G, Magnani P, Zito F, et al, Three-step monoclonal antibody tumour targeting in carcinoembryonic antigenpositive patients. Cancer Res 1991; 51: 5960-6
77. Khawli LA, Alauddin MM, Miller GK, et al, Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabelled streptavidin. Antibody Immunoconjug Radiopharm 1993; 6: 13-27
78. Saga T, Weinstein JN, Jeong JM, et al, Two-step targeting of experimental lung métastases with biotinylated antibody and radiolabelled streptavidin. Cancer Res 1994; 54: 2160-5
79. Bagshawe KD, Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 1987; 56:531-2
80. Senter PD, Wallace PM, Svensson HP, et al. Generation ofcytotoxic agents by targeted enzymes. Bioconjug Chem 1993; 4: 3-9
81. Deonarain MP, Epenetos AA, Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 1994; 70: 786-94
82. Springer CJ, Niculescu-Duvaz I, Mauger AB, et al, The design of prodrugs for antibody-directed enzyme therapy (ADEPT). Proceedings of the Tufton Trust Conference on New Antibody Technology and the Emergence of Useful Cancer Therapy; 1994 Oct 10-11: London. London: Royal Society of Medicine, 1995: 75-7
83. Bagshawe KD, Antibody-directed enzyme prodrug therapy: a review. Drug Dev Res 1995; 34: 220-30
84. Springer CJ, Poon GK, SharmaSK, etal, Analysis of antibodyenzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study. Cell Biophys 1994; 24/25: 193-207
85. Sharma SK, Bagshawe KD, Springer CJ, et al. Antibody-directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers 1991:9:225-31
86. Bagshawe KD, Sharma SK, SpringerCJ, et al. Antibody-directed prodrug therapy (ADEPT): a pilot scale clinical therapy. Tumor Targeting 1995; 1: 17-29
87. Le Doussal JM, Gruaz-Guyon A, Martin M, et al. Targeting of indium-'-labelled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumours hosted in nude mice. Cancer Res 1990: 50: 3445-52
88. Pimm MV, Robins RA, Embleton MJ, et al. A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexatecarrier conjugate. Br J Cancer 1990; 61: 508-13
89. Renner C, Jung W, Sahin U, et al, Cure of xenografted human tumours by bispecific monoclonal antibodies and human Tcells. Science 1994: 264: 833-5
90. Staerz UD, Kanagawa O, Bevan MJ, Hybrid antibodies can target sites for attack by T-cells. Nature 1985; 314: 628-31
91. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumour xenografts following irradiation. Cancer Res 1990; 50: 159-63
92. Order SE, Klein JL, Leichner PK, et al. Radiolabelled antibody in the treatment of primary and metastatic liver malignancies. Recent Res Cancer Res 1986; 100: 307-12
93. Folli S, Pelegrin A, Chalandon Y, et al. Tumour-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993: 53: 829-36
94. Rowlinson-Busza G, Maraveyas A, Epenetos AA, Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. BrJ Cancer 1995:71:660-5
95. Russell SM, Krauer KG, McKenzie IFC, et al, Effect of tumour necrosis factor on the antitumour efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. Cancer Res 1990: 50: 6028-33
96. Smyth MJ, Pieterz A, McKenzie IFC, Increased antitumour effect of immunoconjugates and tumour necrosis factor. Cancer Res 1988:48:3607-12
97. Melton RG, Rowland JA, Pietersz GA, et al, Tumour necrosis factor increases tumour uptake of co-administered anlibodycarboxypeptida.se G2 conjugate. Eur J Cancer 1993: 29A: 1177-83
98. Khawli LA, Miller GK, Epstein AL, Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumours. Cancer 1994; 73: 824-31
99. Zwi LJ, Baguley BC, Gavin JB, et al, The morphological effects of the antitumour agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumour. Pathology 1994:26: 161-9
100. Ching L-M, Joseph WR, Crosier KE, et al, Induction of tumour necrosis factor-ot messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone4-acetic acid (NCS 640488). Cancer Res 1994; 54: 870-2
101. Pedley RB, Begent RHJ, Boden JA, et al. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonie xenograft model. Int J Cancer 1994; 57: 830-5
102. Pedley RB, Boden JA, Boden R, et al, Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow modifying agents. Cancer Res 1996; in press
103. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-35
104. Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4
105. Burrows FJ, Thorpe PE, Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasciilalure. Proc Natl Acad Sei USA 1993: 90: 8996-9000